152 results on '"Rosenblat, Joshua D"'
Search Results
2. Impact of vortioxetine on depressive symptoms moderated by symptoms of anxiety in persons with post-COVID-19 condition: A secondary analysis
3. The association between ketamine and esketamine with alcohol and substance misuse: Reports to the Food and Drug Administration adverse event reporting system (FAERS)
4. Number needed to treat (NNT) for ketamine and esketamine in adults with treatment-resistant depression: A systematic review and meta-analysis
5. Effects of anhedonia on health-related quality of life and functional outcomes in major depressive disorder: A systematic review and meta-analysis
6. Association between cognitive functioning, suicidal ideation and suicide attempts in major depressive disorder, bipolar disorder, schizophrenia and related disorders: A systematic review and meta-analysis
7. A replication study using the World Health Organization pharmacovigilance database (VigiBase®) to evaluate whether an association between ketamine and esketamine and alcohol and substance misuse exists
8. Preclinical and clinical efficacy of kappa opioid receptor antagonists for depression: A systematic review
9. Spectral signatures of psilocybin, lysergic acid diethylamide (LSD) and ketamine in healthy volunteers and persons with major depressive disorder and treatment-resistant depression: A systematic review
10. A comparison between psilocybin and esketamine in treatment-resistant depression using number needed to treat (NNT): A systematic review
11. The rapid antidepressant effectiveness of repeated dose of intravenous ketamine and intranasal esketamine: A post-hoc analysis of pooled real-world data
12. Psilocybin-assisted therapy for depression: A systematic review and meta-analysis
13. Clinical efficacy and safety of Zuranolone (SAGE-217) in individuals with major depressive disorder
14. Predicting outcome with Intranasal Esketamine treatment: A machine-learning, three-month study in Treatment-Resistant Depression (ESK-LEARNING)
15. Real world effectiveness of repeated ketamine infusions for treatment-resistant depression with comorbid borderline personality disorder
16. Evaluating the neural substrates of effort-expenditure for reward in adults with major depressive disorder and obesity
17. Ketamine use in pediatric depression: A systematic review
18. Brain-Derived Neurotrophic Factor (BDNF) as a biomarker of treatment response in patients with Treatment Resistant Depression (TRD): A systematic review & meta-analysis
19. Sex differences in ketamine's therapeutic effects for mood disorders: A systematic review
20. Frequency analysis of symptomatic worsening following ketamine infusions for treatment resistant depression in a real-world sample: Results from the canadian rapid treatment center of excellence
21. Ketamine for psychotic depression: An overview of the glutamatergic system and ketamine's mechanisms associated with antidepressant and psychotomimetic effects
22. The effect of intravenous ketamine on cognitive functions in adults with treatment-resistant major depressive or bipolar disorders: Results from the Canadian rapid treatment center of excellence (CRTCE)
23. The effect of repeated doses of intravenous ketamine on measures of workplace attendance and productivity in adults with major depressive and bipolar disorder: Results from the canadian rapid treatment center of excellence
24. Validation of the McIntyre And Rosenblat Rapid Response Scale (MARRRS) in Adults with Treatment-Resistant Depression Receiving Intravenous Ketamine Treatment
25. A Systematic review of the validity of screening depression through Facebook, Twitter, Instagram, and Snapchat
26. Loneliness-based impaired reward system pathway: Theoretical and clinical analysis and application
27. A simplified 6-Item clinician administered dissociative symptom scale (CADSS-6) for monitoring dissociative effects of sub-anesthetic ketamine infusions
28. Insulin resistance is associated with deficits in hedonic, self-reported cognitive, and psychosocial functional response to antidepressant treatment in individuals with major depressive disorder
29. Effects of infliximab on brain neurochemistry of adults with bipolar depression
30. The Meaningful Change Threshold as Measured by the 16-Item Quick Inventory of Depressive Symptomatology in Adults with Treatment-Resistant Major Depressive and Bipolar Disorder Receiving Intravenous Ketamine
31. The Effect of Loneliness on Distinct Health Outcomes: A Comprehensive Review and Meta-Analysis
32. Changes in symptoms of anhedonia in adults with major depressive or bipolar disorder receiving IV ketamine: Results from the Canadian Rapid Treatment Center of Excellence
33. The effect of intravenous, intranasal, and oral ketamine in mood disorders: A meta-analysis
34. The effectiveness of repeated intravenous ketamine on depressive symptoms, suicidal ideation and functional disability in adults with major depressive disorder and bipolar disorder: Results from the Canadian Rapid Treatment Center of Excellence
35. The utility of smartphone-based, ecological momentary assessment for depressive symptoms
36. Using early changes in cold cognition to predict response to vortioxetine in major depressive disorder
37. Treatment effectiveness and tolerability outcomes that are most important to individuals with bipolar and unipolar depression
38. The effect of pharmacogenomic testing on response and remission rates in the acute treatment of major depressive disorder: A meta-analysis
39. Applications of machine learning algorithms to predict therapeutic outcomes in depression: A meta-analysis and systematic review
40. Cognitive impairment as measured by the THINC-integrated tool (THINC-it): The association with self-reported anxiety in Major Depressive Disorder
41. Efficacy and tolerability of minocycline for depression: A systematic review and meta-analysis of clinical trials
42. Efficacy of antidepressants on measures of workplace functioning in major depressive disorder: A systematic review
43. Cognitive impairment as measured by the THINC-integrated tool (THINC-it): Association with psychosocial function in major depressive disorder
44. Pain and major depressive disorder: Associations with cognitive impairment as measured by the THINC-integrated tool (THINC-it)
45. Medical comorbidity in bipolar disorder: The link with metabolic-inflammatory systems
46. Inflammation as a neurobiological substrate of cognitive impairment in bipolar disorder: Evidence, pathophysiology and treatment implications
47. Real-world effectiveness of repeated ketamine infusions for treatment resistant depression during the COVID-19 pandemic
48. Corrigendum to “Cognitive impairment as measured by the THINC-integrated tool (THINC-it): The association with self-reported anxiety in major depressive disorder” [J. Affect. Disord.. 238, 2018, pages 228–232]
49. Corrigendum to “Applications of machine learning algorithms to predict therapeutic outcomes in depression: A meta-analysis and systematic review.” J Affect Disord. 241 (2018) 519-532
50. Association of history of adverse childhood experiences with irritable bowel syndrome (IBS) in individuals with mood disorders
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.